s How Should We Treat Hyperlipidemia in the Primary Prevention Patient?

Volume 6 - Issue 6

Opinion Biomedical Science and Research Biomedical Science and Research CC by Creative Commons, CC-BY

How Should We Treat Hyperlipidemia in the Primary Prevention Patient?

*Corresponding author: Richard M Fleming, FHHI-OI-Camelot, Los Angeles, CA, USA

Received: December 09, 2019; Published: December 20, 2019

DOI: 10.34297/AJBSR.2019.06.001082


It is reported that Hippocrates said If someone wishes for good health, one must first ask oneself if he is ready to do away with the reasons for his illness. Only then is it possible to help him and Our food should be our medicine and our medicine should be our food. While we may never know if Hippocrates actually made these statements, they seem intuitively valid. In the later half of the 20th Century, changes in dietary and lifestyle practices raised the awareness of the importance of diet and lifestyle and the development of chronic inflammatory diseases – entering the lexicon [1]-and the understanding that it is this inflammatory process which is ultimately responsible for the development of many of our chronic diseases, including coronary artery disease [2], which has gone on to become the number one killer of people worldwide. This case introduces one such example that should remind us to remain vigilant to what Hippocrates said.

Keywords: Primary prevention; Hyperlipidemia; Statins; Diet; Coronary Artery Calcium (CAC) Score; Cardiac catheterization

Clinical Presentation

A middle age gentleman without known history of prior medical problems underwent routine blood work, revealing an elevated total cholesterol level of 146 mg/dl (3.77 mmol/l). He elected not to begin lipid-lowering medications quoting Hippocrates (above). He stated he planned to change his diet and promised to return in 6-months for repeat blood work. Six months later he returned at which time his total cholesterol was 230 mg/ dl (5.95 mmol/l). When he was seen in the clinic, it was discovered that he had been experiencing intermittent chest discomfort. Following recommendations promulgated for decision making in individuals without prior cardiac events and elevated lipids [3], the patient was referred for a coronary artery calcium test (Figure 1), which revealed no evidence of calcium. He was then referred for cardiology evaluation and subsequently underwent cardiac catheterization, revealing a 99% narrowing of his proximal left anterior descending coronary artery (Figure 2) followed by treatment (Figure 2).

Biomedgrid | How Should We Treat Hyperlipidemia, Research

Figure 1: Coronary artery calcium study revealed a Calcium Score of zero.

Biomedgrid | How Should We Treat Hyperlipidemia, Research

Figure 2: Before and after placement of stent in the left anterior descending coronary artery.


In recent years, there has been considerable debate [4, 5, 6] over evidence-based outcomes and the treatment of hyperlipidemia – particularly in the setting of primary prevention. The fundamental question being one of How to best approach the patient with elevated lipids [1] Partially in response to these questions, medical organizations have attempted to develop evolving guidelines utilizing changes in diagnostic tools such as coronary artery calcium (CAC) scores which look for one component of coronary atherosclerosis –sclerosis – but is truly only a test for calcium thereby potentially limiting its application [7]. While the time tested cardiac catheterization – coronary lumenogram-also has its limitations [8, 9, 10], like CAC, when positive for the detection of coronary artery disease (CAD), as it was in this instance, it can be a life saver – particularly when coupled with initial treatment (stenting), as it was in this case. We emphasize the term initial treatment because all too often, patients and sometimes their physicians are under the impression that once a stent is placed, they no longer have CAD.

The very inflammatory plaque that inflamed and impaired the coronary artery, eventually invading the coronary lumen, remains behind after angioplasty (PTCA) or stent placement. As we now know, the act of PTCA with or without stent placement produces iatrogenic damage to the wall of the coronary artery through the outward displacement of the tunica intima, media and externa, with loss of integrity of the external elastic membrane. A small price to pay given the alternatives, but nonetheless a consequence, which should not be ignored or forgotten about. Understanding the continued nidus for further inflammation [1] is of the utmost importance in understanding not only how the patient developed their CAD, but the attention which needs to be given to the subsequent treatment from here out.

What Would You Do Next?

a) Begin intensive statin regimen followed by frequent lipid monitoring to maximize treatment and lower lipid levels.

b) Discuss the changes in the dietary patterns followed by the patient during the 6-month period of time leading up to the development of chest discomfort and increased lipid levels and make dietary changes accordingly.

c) Schedule a myocardial perfusion imaging study to determine the extent of myocardial damage and ischemia.

d) Screen the patient and family members for familial hyperlipidemias and begin treatment of those family members with hyperlipidemia.


All figures are reproduced with the expressed consent of the first author. All patient data is redacted for patient privacy.


Sign up for Newsletter

Sign up for our newsletter to receive the latest updates. We respect your privacy and will never share your email address with anyone else.